

BrightMEM™ corneal allograft

Ocular surface reconstruction with BrightMEM corneal allografts, a foundation for durable epithelial regeneration

BrightMEM anterior keratoplasty (BMAK) is a surgical procedure in which a BrightMEM corneal allograft is transplanted onto the ocular surface to serve as an optimized substrate.

This novel corneal allograft promotes regeneration of the corneal epithelium. BrightMEM is made from Descemet's membrane, which serves as an optimized substrate for protecting the stroma from degradation and promoting regeneration of the corneal epithelium.

BrightMEM expresses proteins that stimulate limbal stem cell growth while resisting degradation. In preclinical studies, BrightMEM supported limbal stem cell expansion and maintained a population of stem cells in the basal corneal epithelium. Clinically, through early 2024, there have been no instances where the corneal epithelium failed to regenerate when treated with BrightMEM.

BrightMEM offers hope as a durable solution for patients with severe corneal disorders through its regenerative properties.



Eversight Academy

Training | Education | Professional Development



On-demand training

Surgeons can access complete BrightMEM product details including a white paper, case study, scientific background, surgical instruction, surgery video and more through Eversight Academy.

Scan the QR code to begin your training.

